Jorge J. Castillo, MD

Articles

Dr Castillo on the Rationale for Evaluating Iopofosine I 131 in Waldenström Macroglobulinemia

April 19th 2024

Jorge J. Castillo, MD, discusses the rationale for evaluating the iopofosine I 131 in Waldenström macroglobulinemia.

Dr Castillo on Acalabrutinib Plus Rituximab in Patients With Anti-MAG IgM Peripheral Neuropathy

February 2nd 2024

Jorge J. Castillo, MD, discusses preliminary data from a phase 2 study of acalabrutinib plus rituximab in patients with IgM symptomatic anti-MAG peripheral neuropathy.

Dr Castillo on the Efficacy of Iopofosine I 131 in Waldenström Macroglobulinemia

January 31st 2024

Jorge J. Castillo, MD, discusses the efficacy of treatment with iopofosine I 131 in patients with Waldenström macroglobulinemia.

Dr Castillo on Ongoing Areas of Investigation in Waldenström Macroglobulinemia

December 19th 2023

Jorge J. Castillo, MD, discusses the ongoing investigation into potential treatment options for patients with Waldenström macroglobulinemia, including iopofosine I-131.

Dr. Castillo on the CLOVER-WaM Trial in Waldenström Macroglobulinemia

June 10th 2022

Jorge J. Castillo, MD, discusses the phase 2 CLOVER WaM trial in Waldenström macroglobulinemia.

Dr. Castillo on the Integration of BTK Inhibitors in Waldenström

September 3rd 2021

Jorge J. Castillo, MD, discusses the integration of BTK inhibitors in Waldenström macroglobulinemia.

Dr. Castillo on the Use of Venetoclax in Waldenstrom Macroglobulinemia

September 15th 2019

Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the results of a multicenter, prospective, phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia.

Dr. Castillo on Emerging Treatment Approaches in Waldenstrom Macroglobulinemia

August 14th 2019

Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School, highlights ongoing research with emerging treatment approaches in Waldenström macroglobulinemia.